

# John M Maris

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6266232/john-m-maris-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

321  
papers

29,477  
citations

87  
h-index

164  
g-index

367  
ext. papers

34,862  
ext. citations

10.5  
avg, IF

6.9  
L-index

#	Paper	IF	Citations
321	Epigenetic state determines inflammatory sensing in neuroblastoma.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2022</b> , 119,	11.5	3
320	Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency.. <i>Nature Medicine</i> , <b>2022</b> ,	50.5	2
319	Paraneoplastic myasthenia gravis and pemphigus associated with follicular dendritic cell sarcoma leading to cardiorespiratory collapse in a 7-year-old.. <i>Pediatric Blood and Cancer</i> , <b>2022</b> , e29723	3	0
318	Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs. <i>Nature</i> , <b>2021</b> , 599, 477-484	50.4	14
317	GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity.. <i>Cancer Cell</i> , <b>2021</b> ,	24.3	10
316	Stage 4S Neuroblastoma: Molecular, Histologic, and Immunohistochemical Characteristics and Presence of 2 Distinct Patterns of MYCN Protein Overexpression-A Report From the Children's Oncology Group. <i>American Journal of Surgical Pathology</i> , <b>2021</b> , 45, 1075-1081	6.7	2
315	Epigenetic regulator BMI1 promotes alveolar rhabdomyosarcoma proliferation and constitutes a novel therapeutic target. <i>Molecular Oncology</i> , <b>2021</b> , 15, 2156-2171	7.9	2
314	Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE. <i>European Journal of Cancer</i> , <b>2021</b> , 146, 115-124	7.5	3
313	A G316A Polymorphism in the Ornithine Decarboxylase Gene Promoter Modulates MYCN-Driven Childhood Neuroblastoma. <i>Cancers</i> , <b>2021</b> , 13,	6.6	1
312	Testing of B7-H3 targeting antibody-drug conjugate (ADC) MGC018 in models of pediatric solid tumors by the Pediatric Preclinical Testing Consortium (PPTC).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 10037-10037	2.2	1
311	IMMU-16. TARGETING GLYPICAN 2 (GPC2) ON PEDIATRIC MALIGNANT BRAIN TUMORS WITH MRNA CAR T CELLS. <i>Neuro-Oncology</i> , <b>2021</b> , 23, i30-i30	1	1
310	Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 3229-3241	2.2	15
309	A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational epitope. <i>Cell Reports Medicine</i> , <b>2021</b> , 2, 100344	18	5
308	Refining immunotherapeutic approaches to high-risk neuroblastoma based on tumor genomic profiles. <i>Molecular Oncology</i> , <b>2021</b> , 15, 347-349	7.9	
307	PARP Targeted Alpha-Particle Therapy Enhances Response to PD-1 Immune-Checkpoint Blockade in a Syngeneic Mouse Model of Glioblastoma. <i>ACS Pharmacology and Translational Science</i> , <b>2021</b> , 4, 344-351	5.9	4
306	Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 2179-2189	12.9	30
305	GAS7 Deficiency Promotes Metastasis in MYCN-Driven Neuroblastoma. <i>Cancer Research</i> , <b>2021</b> , 81, 2995-3007	10.7	7

304	Mutations in the RAS/MAPK Pathway Drive Replication Repair-Deficient Hypermutated Tumors and Confer Sensitivity to MEK Inhibition. <i>Cancer Discovery</i> , <b>2021</b> , 11, 1454-1467	24.4	6
303	HACE1 blocks HIF1 $\alpha$ accumulation under hypoxia in a RAC1 dependent manner. <i>Oncogene</i> , <b>2021</b> , 40, 1988-2001	9.2	1
302	The B7-H3-Targeting Antibody-Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 2938-2946	12.9	16
301	Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 3506-3514	2.2	7
300	Drugging the "Undruggable" MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers. <i>Cancer Research</i> , <b>2021</b> , 81, 1627-1632	10.1	7
299	annoFuse: an R Package to annotate, prioritize, and interactively explore putative oncogenic RNA fusions. <i>BMC Bioinformatics</i> , <b>2020</b> , 21, 577	3.6	0
298	Identification of SARS-CoV-2 Vaccine Epitopes Predicted to Induce Long-Term Population-Scale Immunity. <i>Cell Reports Medicine</i> , <b>2020</b> , 1, 100036	18	39
297	Immune-Based Approaches for the Treatment of Pediatric Malignancies. <i>Annual Review of Cancer Biology</i> , <b>2020</b> , 4, 353-370	13.3	2
296	Crossing Oceans: Preclinical Collaboration to Improve Pediatric Drug Development. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2020</b> , 40, 1-8	7.1	
295	Immunogenicity and Immune Silence in Human Cancer. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 69	8.4	9
294	CAMKV Is a Candidate Immunotherapeutic Target in Amplified Neuroblastoma. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 302	5.3	3
293	Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma. <i>European Journal of Cancer</i> , <b>2020</b> , 136, 52-68	7.5	14
292	Mitochondrial DNA Haplogroups and Susceptibility to Neuroblastoma. <i>Journal of the National Cancer Institute</i> , <b>2020</b> , 112, 1259-1266	9.7	5
291	Preclinical evaluation of the combination of AZD1775 and irinotecan against selected pediatric solid tumors: A Pediatric Preclinical Testing Consortium report. <i>Pediatric Blood and Cancer</i> , <b>2020</b> , 67, e28098	3	6
290	Tatton-Brown-Rahman syndrome: Six individuals with novel features. <i>American Journal of Medical Genetics, Part A</i> , <b>2020</b> , 182, 673-680	2.5	3
289	Rare copy number variants in over 100,000 European ancestry subjects reveal multiple disease associations. <i>Nature Communications</i> , <b>2020</b> , 11, 255	17.4	17
288	Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312). <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 1213-1219	12.9	24
287	Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 2160-2169	2.2	37

286	Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma. <i>Nature Medicine</i> , <b>2020</b> , 26, 720-731	50.5	60
285	LIN28B promotes neuroblastoma metastasis and regulates PDZ binding kinase. <i>Neoplasia</i> , <b>2020</b> , 22, 231-241	2.4	9
284	The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution. <i>Cell</i> , <b>2020</b> , 181, 236-249	56.2	140
283	Phase I trial of lorlatinib in patients with ALK-driven refractory or relapsed neuroblastoma: A New Approaches to Neuroblastoma Consortium study.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 10504-10504	2.2	9
282	Clinical significance of serial tumor next generation sequencing (NGS) in 155 pediatric cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e13666-e13666	2.2	0
281	Image-guided core needle biopsy for relapsed and refractory neuroblastoma: A focus on sample adequacy for genetic sequencing.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e22521-e22521	2.2	
280	A phase I study of Aurora kinase A inhibitor LY3295668 erbumine as a single agent and in combination in patients with relapsed/refractory neuroblastoma.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, TPS10561-TPS10561	2.2	
279	Outcomes and toxicities in patients (pts) non-randomly assigned to immunotherapy Children's Oncology Group (COG) ANBL0032.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 10523-10523	2.2	
278	PARP-1-Targeted Auger Emitters Display High-LET Cytotoxic Properties In Vitro but Show Limited Therapeutic Utility in Solid Tumor Models of Human Neuroblastoma. <i>Journal of Nuclear Medicine</i> , <b>2020</b> , 61, 850-856	8.9	16
277	Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations. <i>Nature Communications</i> , <b>2020</b> , 11, 5183	17.4	31
276	Somatic structural variation targets neurodevelopmental genes and identifies as a tumor suppressor in neuroblastoma. <i>Genome Research</i> , <b>2020</b> , 30, 1228-1242	9.7	7
275	Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19. <i>Leukemia</i> , <b>2020</b> , 34, 1202-1207	10.7	29
274	Limited antitumor activity of combined BET and MEK inhibition in neuroblastoma. <i>Pediatric Blood and Cancer</i> , <b>2020</b> , 67, e28267	3	7
273	High throughput pMHC-I tetramer library production using chaperone-mediated peptide exchange. <i>Nature Communications</i> , <b>2020</b> , 11, 1909	17.4	19
272	Epigenomic profiling of neuroblastoma cell lines. <i>Scientific Data</i> , <b>2020</b> , 7, 116	8.2	9
271	Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma. <i>Cancer Research</i> , <b>2020</b> , 80, 2663-2675	10.1	25
270	Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2019</b> , 322, 746-755	27.4	104
269	Exploring Shared Susceptibility between Two Neural Crest Cells Originating Conditions: Neuroblastoma and Congenital Heart Disease. <i>Genes</i> , <b>2019</b> , 10,	4.2	8

268	Clinical utility of custom-designed NGS panel testing in pediatric tumors. <i>Genome Medicine</i> , <b>2019</b> , 11, 32	14.4	45
267	Targeting PARP-1 with Alpha-Particles Is Potently Cytotoxic to Human Neuroblastoma in Preclinical Models. <i>Molecular Cancer Therapeutics</i> , <b>2019</b> , 18, 1195-1204	6.1	21
266	IMMU-04. DEVELOPMENT OF GPC2-DIRECTED CHIMERIC ANTIGEN RECEPTOR THERAPY FOR PEDIATRIC BRAIN TUMORS WITH IN VITRO TRANSCRIBED mRNA. <i>Neuro-Oncology</i> , <b>2019</b> , 21, ii93-ii93	1	78
265	Outcomes After Proton Therapy for Treatment of Pediatric High-Risk Neuroblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2019</b> , 104, 401-408	4	15
264	Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children's Oncology Group Study ANBL0531. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 115-124	2.2	26
263	Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 3243-3255	2.2	24
262	Neuroblastoma in relation to joint effects of vitamin A and maternal and offspring variants in vitamin A-related genes: A report of the Children's Oncology Group. <i>Cancer Epidemiology</i> , <b>2019</b> , 61, 165-171	2.8	3
261	ATRX In-Frame Fusion Neuroblastoma Is Sensitive to EZH2 Inhibition via Modulation of Neuronal Gene Signatures. <i>Cancer Cell</i> , <b>2019</b> , 36, 512-527.e9	24.3	25
260	Immunotherapy for pediatric brain tumors: past and present. <i>Neuro-Oncology</i> , <b>2019</b> , 21, 1226-1238	1	14
259	Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design. <i>Cell Reports</i> , <b>2019</b> , 29, 1675-1689.e9	10.6	51
258	YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling. <i>Cancer Research</i> , <b>2019</b> , 79, 6204-6214	10.1	26
257	Antitumor Activity and Tolerability of hu14.18-IL2 with GMCSF and Isotretinoin in Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Phase II Study. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 6044-6051	12.9	10
256	A revised Children's Oncology Group (COG) neuroblastoma risk classification system: Report from the COG biology study ANBL00B1.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 10012-10012	2.2	0
255	PRIMA-1-induced neuroblastoma cell death is modulated by p53 and mycn through glutathione level. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2019</b> , 38, 69	12.8	8
254	When Cold Is Hot: Immune Checkpoint Inhibition Therapy for Rhabdoid Tumors. <i>Cancer Cell</i> , <b>2019</b> , 36, 575-576	24.3	3
253	Combined innate and adaptive immunotherapy overcomes resistance of immunologically cold syngeneic murine neuroblastoma to checkpoint inhibition <b>2019</b> , 7, 344		22
252	ASCL1 is a MYCN- and LMO1-dependent member of the adrenergic neuroblastoma core regulatory circuitry. <i>Nature Communications</i> , <b>2019</b> , 10, 5622	17.4	29
251	Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 2278-2289	12.9	38

250	The challenge of defining "ultra-high-risk" neuroblastoma. <i>Pediatric Blood and Cancer</i> , <b>2019</b> , 66, e27556	3	22
249	CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 2560-2574	12.9	196
248	Cross-Cohort Analysis Identifies a TEAD4-MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma. <i>Cancer Discovery</i> , <b>2018</b> , 8, 582-599	24.4	58
247	Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients. <i>Journal of the National Cancer Institute</i> , <b>2018</b> , 110, 1084-1093	9.7	43
246	Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours. <i>Nature</i> , <b>2018</b> , 555, 371-376	50.4	380
245	Rare MYC-amplified Neuroblastoma With Large Cell Histology. <i>Pediatric and Developmental Pathology</i> , <b>2018</b> , 21, 461-466	2.2	9
244	QuantumClone: clonal assessment of functional mutations in cancer based on a genotype-aware method for clonal reconstruction. <i>Bioinformatics</i> , <b>2018</b> , 34, 1808-1816	7.2	16
243	Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 189-196	12.9	36
242	A Recurrent Mutation in Anaplastic Lymphoma Kinase with Distinct Neoepitope Conformations. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 99	8.4	16
241	A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 1355	8.4	49
240	Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 6142-6149	12.9	39
239	Fine mapping of 2q35 high-risk neuroblastoma locus reveals independent functional risk variants and suggests full-length BARD1 as tumor-suppressor. <i>International Journal of Cancer</i> , <b>2018</b> , 143, 2828-2837	7.5	34
238	Phase II trial of irinotecan/temozolomide/dinutuximab/granulocyte macrophage colony stimulating factor (I/T/DIN/GMCSF) in children with relapsed/refractory neuroblastoma (NBL): A report from the Children's Oncology Group (COG).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 10508-10508	2.2	3
237	MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children's oncology group. <i>Oncotarget</i> , <b>2018</b> , 9, 6416-6432	3.3	19
236	Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial. <i>The Lancet Child and Adolescent Health</i> , <b>2018</b> , 2, 25-34	14.5	19
235	Transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: A case series. <i>Pediatric Blood and Cancer</i> , <b>2018</b> , 65, e26732	3	14
234	TBIO-29. PedcBioPortal, A CANCER DATA VISUALIZATION TOOL FOR INTEGRATIVE PEDIATRIC CANCER ANALYSES. <i>Neuro-Oncology</i> , <b>2018</b> , 20, i186-i186	1	78
233	MBRS-57. TARGETING METABOLIC ADAPTATION IN MYC/MYCN AMPLIFIED PEDIATRIC MEDULLOBLASTOMA AND NEUROBLASTOMA. <i>Neuro-Oncology</i> , <b>2018</b> , 20, i140-i140	1	78

232	Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T-Cell Receptors in High-Risk -Not-Amplified Human Neuroblastoma. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 5673-5684	12.9	45
231	Genomic Profiling of a Large Set of Diverse Pediatric Cancers Identifies Known and Novel Mutations across Tumor Spectra. <i>Cancer Research</i> , <b>2017</b> , 77, 509-519	10.1	60
230	Association Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases: A Mendelian Randomization Study. <i>JAMA Oncology</i> , <b>2017</b> , 3, 636-651	13.4	236
229	Genetic susceptibility to neuroblastoma. <i>Current Opinion in Genetics and Development</i> , <b>2017</b> , 42, 81-90	4.9	57
228	Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , <b>2017</b> , 18, 946-957	21.7	133
227	MYCN amplified neuroblastoma requires the mRNA translation regulator eEF2 kinase to adapt to nutrient deprivation. <i>Cell Death and Differentiation</i> , <b>2017</b> , 24, 1564-1576	12.7	14
226	Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues. <i>Cancer</i> , <b>2017</b> , 123, 3807-3815	6.4	99
225	MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , <b>2017</b> , 64, e26545	3	25
224	Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines. <i>Scientific Data</i> , <b>2017</b> , 4, 170033	8.2	56
223	Dexmedetomidine does not interfere with meta-iodobenzylguanidine (MIBG) uptake at clinically relevant concentrations. <i>Pediatric Blood and Cancer</i> , <b>2017</b> , 64, e26268	3	1
222	Comprehensive Analysis of Hypermutation in Human Cancer. <i>Cell</i> , <b>2017</b> , 171, 1042-1056.e10	56.2	417
221	Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2580-2587	2.2	142
220	LMO1 Synergizes with MYCN to Promote Neuroblastoma Initiation and Metastasis. <i>Cancer Cell</i> , <b>2017</b> , 32, 310-323.e5	24.3	52
219	Common variants in MMP20 at 11q22.2 predispose to 11q deletion and neuroblastoma risk. <i>Nature Communications</i> , <b>2017</b> , 8, 569	17.4	19
218	Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma. <i>Cancer Cell</i> , <b>2017</b> , 32, 295-309.e12	24.3	100
217	Evaluation of Genetic Predisposition for MYCN-Amplified Neuroblastoma. <i>Journal of the National Cancer Institute</i> , <b>2017</b> , 109,	9.7	17
216	11q deletion in neuroblastoma: a review of biological and clinical implications. <i>Molecular Cancer</i> , <b>2017</b> , 16, 114	42.1	53
215	Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program. <i>Pediatric Blood and Cancer</i> , <b>2017</b> , 64, e26304	3	14

214	Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , <b>2017</b> , 64, e26263	3	11
213	Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 1785-1796	12.9	48
212	A phase 1, open-label, dose escalation study of enoblituzumab (MGA271) in pediatric patients with B7-H3-expressing relapsed or refractory solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, TPS2596-TPS2596	23	2597
211	Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with (131)I-metaiodobenzylguanidine. <i>European Journal of Cancer</i> , <b>2016</b> , 66, 144-52	7.5	18
210	Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis. <i>Cancer Research</i> , <b>2016</b> , 76, 5798-5809	10.1	44
209	Neuroblastoma. <i>Nature Reviews Disease Primers</i> , <b>2016</b> , 2, 16078	51.1	524
208	Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , <b>2016</b> , 63, 276-86	3	17
207	Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program. <i>Pediatric Blood and Cancer</i> , <b>2016</b> , 63, 443-50	3	
206	MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma. <i>Cancer Letters</i> , <b>2016</b> , 371, 214-24	9.9	28
205	Differential killing of CD56-expressing cells by drug-conjugated human antibodies targeting membrane-distal and membrane-proximal non-overlapping epitopes. <i>MABs</i> , <b>2016</b> , 8, 799-810	6.6	23
204	Imaging genomics in cancer research: limitations and promises. <i>British Journal of Radiology</i> , <b>2016</b> , 89, 20151030	3.4	72
203	Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 1368-75	2.2	83
202	Phase II randomized trial of irinotecan/temozolomide (I/T) with temsirolimus (TEM) or dinutuximab plus granulocyte colony stimulating factor (DIN/GMCSF) in children with refractory or relapsed neuroblastoma: A report from the Children's Oncology Group (COG).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 10502-10502	2.2	4
201	Assessment of PD-L1 expression and tumor associated immune cells in pediatric cancer tissues.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 11542-11542	2.2	2
200	Impact of KIR/KIR ligand genotype for neuroblastoma patients in a phase III COG immunotherapy trial.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e14014-e14014	2.2	1
199	A phase III randomized clinical trial (RCT) of tandem myeloablative autologous stem cell transplant (ASCT) using peripheral blood stem cell (PBSC) as consolidation therapy for high-risk neuroblastoma (HR-NB): A Children's Oncology Group (COG) study.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, LBA3-LBA3	2.2	15
198	A phase III randomized clinical trial (RCT) of tandem myeloablative autologous stem cell transplant (ASCT) using peripheral blood stem cell (PBSC) as consolidation therapy for high-risk neuroblastoma (HR-NB): A Children's Oncology Group (COG) study.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, LBA3-LBA3	2.2	27
197	Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome. <i>PLoS Genetics</i> , <b>2016</b> , 12, e1006501	6	64



196	Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma. <i>PLoS ONE</i> , <b>2016</b> , 11, e0147682	25
195	Clinical, biologic, and outcome differences according to MIBG avidity in children with neuroblastoma: A report from the Children's Oncology Group (COG).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 10526-10526	2.2
194	Phase II study of alisertib, irinotecan, and temozolomide in children with relapsed and refractory neuroblastoma: A report from the New Approaches to Neuroblastoma Therapy (NANT) consortium.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 10556-10556	2.2
193	Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma. <i>PLoS ONE</i> , <b>2016</b> , 11, e0161039	3.7 18
192	Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program. <i>Pediatric Blood and Cancer</i> , <b>2016</b> , 63, 1744-52	3 20
191	A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma. <i>Pediatric Blood and Cancer</i> , <b>2016</b> , 63, 1349-56	3 46
190	A family-based study of gene variants and maternal folate and choline in neuroblastoma: a report from the Children's Oncology Group. <i>Cancer Causes and Control</i> , <b>2016</b> , 27, 1209-18	2.8 6
189	Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations. <i>Cancer</i> , <b>2016</b> , 122, 20-33	6.4 121
188	Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. <i>Nature Genetics</i> , <b>2015</b> , 47, 864-863	313
187	CASC15-S Is a Tumor Suppressor lncRNA at the 6p22 Neuroblastoma Susceptibility Locus. <i>Cancer Research</i> , <b>2015</b> , 75, 3155-66	10.1 110
186	Identifying rare events in rare diseases. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 1782-5	12.9 2
185	131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II study. <i>Biology of Blood and Marrow Transplantation</i> , <b>2015</b> , 21, 673-81	4.7 64
184	A LIN28B-RAN-AURKA Signaling Network Promotes Neuroblastoma Tumorigenesis. <i>Cancer Cell</i> , <b>2015</b> , 28, 599-609	24.3 74
183	Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. <i>Cancer Discovery</i> , <b>2015</b> , 5, 1282-95	24.4 713
182	G-CSF Is a Cancer Stem Cell-Specific Growth Factor-Letter. <i>Cancer Research</i> , <b>2015</b> , 75, 3991	10.1 4
181	MYC Disrupts the Circadian Clock and Metabolism in Cancer Cells. <i>Cell Metabolism</i> , <b>2015</b> , 22, 1009-19	24.6 152
180	Genetic predisposition to neuroblastoma mediated by a LMO1 super-enhancer polymorphism. <i>Nature</i> , <b>2015</b> , 528, 418-21	50.4 201
179	Initial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetaxel, by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , <b>2015</b> , 62, 1897-905	3 13

178	Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673. <i>Pediatric Blood and Cancer</i> , <b>2015</b> , 62, 91-8	3	55
177	Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin-bound (nab) paclitaxel (Abraxane®) by the Pediatric Preclinical Testing Program (PPTP). <i>Pediatric Blood and Cancer</i> , <b>2015</b> , 62, 1214-21	3	27
176	Treatment of neuroblastoma in congenital central hypoventilation syndrome with a PHOX2B polyalanine repeat expansion mutation: New twist on a neurocristopathy syndrome. <i>Pediatric Blood and Cancer</i> , <b>2015</b> , 62, 2007-10	3	9
175	Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastoma. <i>Pediatric Blood and Cancer</i> , <b>2015</b> , 62, 1739-46	3	23
174	Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 819-32	12.9	85
173	Ataxia-telangiectasia mutated (ATM) silencing promotes neuroblastoma progression through a MYCN independent mechanism. <i>Oncotarget</i> , <b>2015</b> , 6, 18558-76	3.3	22
172	Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program. <i>Pediatric Blood and Cancer</i> , <b>2014</b> , 61, 158-64	3	38
171	Rare variants in TP53 and susceptibility to neuroblastoma. <i>Journal of the National Cancer Institute</i> , <b>2014</b> , 106, dju047	9.7	83
170	Common genetic variants in NEFL influence gene expression and neuroblastoma risk. <i>Cancer Research</i> , <b>2014</b> , 74, 6913-24	10.1	69
169	Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: a report from the Children's Oncology Group (ANBL0621). <i>Pediatric Blood and Cancer</i> , <b>2014</b> , 61, 990-6	3	13
168	The promises and pitfalls of genetic epidemiologic approaches to pediatric cancers: lessons from MDM2. <i>Pediatric Blood and Cancer</i> , <b>2014</b> , 61, 1717-8	3	
167	Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , <b>2014</b> , 61, 1972-9	3	7
166	Inactivation of SMC2 shows a synergistic lethal response in MYCN-amplified neuroblastoma cells. <i>Cell Cycle</i> , <b>2014</b> , 13, 1115-31	4.7	25
165	Reply to N.-K.V. Cheung et al. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 4174-5	2.2	5
164	Maintaining outstanding outcomes using response- and biology-based therapy for intermediate-risk neuroblastoma: A report from the Children's Oncology Group study ANBL0531.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 10006-10006	2.2	4
163	A comprehensive safety trial of chimeric antibody 14.18 (ch14.18) with GM-CSF, IL-2, and isotretinoin in high-risk neuroblastoma patients following myeloablative therapy: A Children's Oncology Group study.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 10044-10044	2.2	8
162	Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program. <i>Pediatric Blood and Cancer</i> , <b>2013</b> , 60, 633-41	3	49
161	Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. <i>Lancet Oncology</i> , <b>2013</b> , 14, 472-80	21.7	510

160	Children's Oncology Group's 2013 blueprint for research: neuroblastoma. <i>Pediatric Blood and Cancer</i> , <b>2013</b> , 60, 985-93	3	226
159	Mitogen-activated protein kinase (MEK/ERK) inhibition sensitizes cancer cells to centromere-associated protein E inhibition. <i>International Journal of Cancer</i> , <b>2013</b> , 132, E149-57	7.5	12
158	Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. <i>Lancet Oncology, The</i> , <b>2013</b> , 14, 999-1008	21.7	205
157	Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , <b>2013</b> , 60, 1325-32	3	66
156	The genetic landscape of high-risk neuroblastoma. <i>Nature Genetics</i> , <b>2013</b> , 45, 279-84	36.3	717
155	Semiquantitative mlBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group. <i>Journal of Nuclear Medicine</i> , <b>2013</b> , 54, 541-8	8.9	135
154	Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 6173-82	12.9	265
153	Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma. <i>DMM Disease Models and Mechanisms</i> , <b>2013</b> , 6, 373-82	4.1	41
152	Targeting MYCN: a good BET for improving neuroblastoma therapy?. <i>Cancer Discovery</i> , <b>2013</b> , 3, 255-7	24.4	13
151	Combination therapy targeting the Chk1 and Wee1 kinases shows therapeutic efficacy in neuroblastoma. <i>Cancer Research</i> , <b>2013</b> , 73, 776-84	10.1	92
150	Replication of GWAS-identified neuroblastoma risk loci strengthens the role of BARD1 and affirms the cumulative effect of genetic variations on disease susceptibility. <i>Carcinogenesis</i> , <b>2013</b> , 34, 605-11	4.6	82
149	Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology Group. <i>Cancer</i> , <b>2013</b> , 119, 3718-26	6.4	54
148	Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMG901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , <b>2013</b> , 60, 1860-7	3	21
147	Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortium. <i>Pediatric Blood and Cancer</i> , <b>2013</b> , 60, 1801-8	3	62
146	Trans-population analysis of genetic mechanisms of ethnic disparities in neuroblastoma survival. <i>Journal of the National Cancer Institute</i> , <b>2013</b> , 105, 302-9	9.7	25
145	ATF4 regulates MYC-mediated neuroblastoma cell death upon glutamine deprivation. <i>Cancer Cell</i> , <b>2012</b> , 22, 631-44	24.3	236
144	Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma. <i>Nature Genetics</i> , <b>2012</b> , 44, 1126-30	36.3	198
143	New strategies in refractory and recurrent neuroblastoma: translational opportunities to impact patient outcome. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 2423-8	12.9	60

142	A three-gene expression signature model for risk stratification of patients with neuroblastoma. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 2012-23	12.9	40
141	Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 1842-8	2.2	128
140	Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , <b>2012</b> , 58, 729-35	3	41
139	Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , <b>2012</b> , 58, 566-71	3	25
138	Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program. <i>Pediatric Blood and Cancer</i> , <b>2012</b> , 58, 636-9	3	66
137	Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , <b>2012</b> , 58, 916-23	3	28
136	Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , <b>2012</b> , 59, 749-52	3	16
135	Replication of neuroblastoma SNP association at the BARD1 locus in African-Americans. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2012</b> , 21, 658-63	4	48
134	Dose escalation study of no-carrier-added <sup>131</sup> I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial. <i>Journal of Nuclear Medicine</i> , <b>2012</b> , 53, 1155-63	8.9	54
133	Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I Consortium study. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 6058-64	12.9	93
132	Common variation at BARD1 results in the expression of an oncogenic isoform that influences neuroblastoma susceptibility and oncogenicity. <i>Cancer Research</i> , <b>2012</b> , 72, 2068-78	10.1	75
131	Phase I study of vincristine, irinotecan, and <sup>131</sup> I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 2679-86	12.9	56
130	Evaluation of Norepinephrine Transporter Expression and Metaiodobenzylguanidine Avidity in Neuroblastoma: A Report from the Children's Oncology Group. <i>International Journal of Molecular Imaging</i> , <b>2012</b> , 2012, 250834		36
129	A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children's Oncology Group study. <i>Annals of Surgery</i> , <b>2012</b> , 256, 573-80	7.8	113
128	Outcome analysis of non-high-risk neuroblastoma patients enrolled on Children's Oncology Group trials P9641 and A3961.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 9533-9533	2.2	
127	Relationship of divergent ancestral genetic variation on chromosome 6p22 and racial disparities in survival in neuroblastoma.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 9516-9516	2.2	
126	Pharmacokinetics (PK) of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 9576-9576	2.2	
125	Phenotype restricted genome-wide association study using a gene-centric approach identifies three low-risk neuroblastoma susceptibility Loci. <i>PLoS Genetics</i> , <b>2011</b> , 7, e1002026	6	123

124	Integrative genomics identifies LMO1 as a neuroblastoma oncogene. <i>Nature</i> , <b>2011</b> , 469, 216-20	50.4	231
123	Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2011</b> , 68, 1057-65	3.5	64
122	Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2011</b> , 68, 1291-304	3.5	80
121	Preclinical evaluation of lestaurtinib (CEP-701) in combination with retinoids for neuroblastoma. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2011</b> , 68, 1469-75	3.5	15
120	Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , <b>2011</b> , 56, 595-603	3	59
119	Thyroid and hepatic function after high-dose 131 I-metaiodobenzylguanidine (131 I-MIBG) therapy for neuroblastoma. <i>Pediatric Blood and Cancer</i> , <b>2011</b> , 56, 191-201	3	41
118	Safety and efficacy of tandem 131I-metaiodobenzylguanidine infusions in relapsed/refractory neuroblastoma. <i>Pediatric Blood and Cancer</i> , <b>2011</b> , 57, 1124-9	3	38
117	Genome-wide linkage analysis to identify genetic modifiers of ALK mutation penetrance in familial neuroblastoma. <i>Human Heredity</i> , <b>2011</b> , 71, 135-9	1.1	23
116	Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma. <i>Science Translational Medicine</i> , <b>2011</b> , 3, 108ra114	17.5	175
115	RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2011</b> , 108, 3336-41	11.5	196
114	Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 208-13	2.2	98
113	Optimal False Discovery Rate Control for Dependent Data. <i>Statistics and Its Interface</i> , <b>2011</b> , 4, 417-430	0.4	18
112	Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program. <i>Molecular Cancer Therapeutics</i> , <b>2010</b> , 9, 101-12	6.1	84
111	Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. <i>Cancer Research</i> , <b>2010</b> , 70, 9554-61	10.1	138
110	Serial transcriptome analysis and cross-species integration identifies centromere-associated protein E as a novel neuroblastoma target. <i>Cancer Research</i> , <b>2010</b> , 70, 2749-58	10.1	41
109	Lestaurtinib enhances the antitumor efficacy of chemotherapy in murine xenograft models of neuroblastoma. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 1478-85	12.9	51
108	Combinatorial regulation of neuroblastoma tumor progression by N-Myc and hypoxia inducible factor HIF-1alpha. <i>Cancer Research</i> , <b>2010</b> , 70, 10351-61	10.1	113
107	Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 4969-75	2.2	184

106	Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. <i>New England Journal of Medicine</i> , <b>2010</b> , 363, 1313-23	59.2	190
105	Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. <i>New England Journal of Medicine</i> , <b>2010</b> , 363, 1324-34	59.2	1144
104	Recent advances in neuroblastoma. <i>New England Journal of Medicine</i> , <b>2010</b> , 362, 2202-11	59.2	1210
103	Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 1532-41	12.9	69
102	A hidden Markov random field model for genome-wide association studies. <i>Biostatistics</i> , <b>2010</b> , 11, 139-50.7	3	33
101	MEK Inhibitors Work Better. <i>Cancer Cell</i> , <b>2010</b> , 18, 103-105	24.3	2
100	Initial testing of topotecan by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , <b>2010</b> , 54, 707-15	3	34
99	Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program. <i>Pediatric Blood and Cancer</i> , <b>2010</b> , 54, 921-6	3	79
98	Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). <i>Pediatric Blood and Cancer</i> , <b>2010</b> , 55, 26-34	3	177
97	Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , <b>2010</b> , 55, 295-303	3	56
96	Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program. <i>Pediatric Blood and Cancer</i> , <b>2010</b> , 55, 668-77	3	82
95	Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , <b>2010</b> , 55, 1126-33	3	47
94	Molecular Therapy for Neuroblastoma <b>2010</b> , 351-371		
93	Iodine-131--metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 1020-5	2.2	94
92	Inhibition of ALK signaling for cancer therapy. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 5609-14	12.9	125
91	Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 1290-6	2.2	66
90	Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 5343-9	2.2	77
89	Unholy matrimony: Aurora A and N-Myc as malignant partners in neuroblastoma. <i>Cancer Cell</i> , <b>2009</b> , 15, 5-6	24.3	18

88	Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , <b>2009</b> , 52, 44-50	3	41
87	Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , <b>2009</b> , 53, 505-8	3	44
86	Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG. <i>Pediatric Blood and Cancer</i> , <b>2009</b> , 53, 563-9	3	54
85	Copy number variation at 1q21.1 associated with neuroblastoma. <i>Nature</i> , <b>2009</b> , 459, 987-91	50.4	285
84	Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. <i>Nature Genetics</i> , <b>2009</b> , 41, 718-23	36.3	226
83	Genomic copy number determination in cancer cells from single nucleotide polymorphism microarrays based on quantitative genotyping corrected for aneuploidy. <i>Genome Research</i> , <b>2009</b> , 19, 276-83	9.7	62
82	Identification of ALK as a major familial neuroblastoma predisposition gene. <i>Nature</i> , <b>2008</b> , 455, 930-5	50.4	960
81	Screening for neuroblastoma: a resurrected idea?. <i>Lancet, The</i> , <b>2008</b> , 371, 1142-3	40	16
80	Molecular characterization of the pediatric preclinical testing panel. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 4572-83	12.9	107
79	High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2008</b> , 105, 14094-9	11.5	133
78	The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. <i>Genes and Development</i> , <b>2008</b> , 22, 884-93	12.6	259
77	A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 1111-5	12.9	42
76	A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene. <i>Molecular Cancer Research</i> , <b>2008</b> , 6, 735-42	6.6	262
75	Adjustment of genomic waves in signal intensities from whole-genome SNP genotyping platforms. <i>Nucleic Acids Research</i> , <b>2008</b> , 36, e126	20.1	255
74	Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. <i>New England Journal of Medicine</i> , <b>2008</b> , 358, 2585-93	59.2	224
73	Effect of sleep stage on breathing in children with central hypoventilation. <i>Journal of Applied Physiology</i> , <b>2008</b> , 105, 44-53	3.7	44
72	Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , <b>2008</b> , 50, 37-45	3	106
71	Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , <b>2008</b> , 50, 581-7	3	107

70	Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , <b>2008</b> , 50, 799-805	3	153
69	Initial testing of dasatinib by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , <b>2008</b> , 50, 1198-206	3	63
68	Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , <b>2008</b> , 50, 1181-9	3	97
67	Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , <b>2008</b> , 50, 1190-7	3	155
66	Neural cell adhesion molecule (NCAM) isoform expression is associated with neuroblastoma differentiation status. <i>Pediatric Blood and Cancer</i> , <b>2008</b> , 51, 10-6	3	33
65	Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , <b>2008</b> , 51, 42-8	3	79
64	Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays. <i>PLoS ONE</i> , <b>2007</b> , 2, e255	3.7	95
63	Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression. <i>Genes Chromosomes and Cancer</i> , <b>2007</b> , 46, 936-49	5	83
62	The pediatric preclinical testing program: description of models and early testing results. <i>Pediatric Blood and Cancer</i> , <b>2007</b> , 49, 928-40	3	371
61	Prominent microvascular proliferation in clinically aggressive neuroblastoma. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 3499-506	12.9	30
60	Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 1054-60	2.2	194
59	Neuroblastoma. <i>Lancet, The</i> , <b>2007</b> , 369, 2106-20	40	1542
58	Immunosurveillance and survivin-specific T-cell immunity in children with high-risk neuroblastoma. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 5725-34	2.2	72
57	STAC: A method for testing the significance of DNA copy number aberrations across multiple array-CGH experiments. <i>Genome Research</i> , <b>2006</b> , 16, 1149-58	9.7	131
56	The H <sup>+</sup> -linked monocarboxylate transporter (MCT1/SLC16A1): a potential therapeutic target for high-risk neuroblastoma. <i>Molecular Pharmacology</i> , <b>2006</b> , 70, 2108-15	4.3	135
55	High-resolution analysis of chromosomal breakpoints and genomic instability identifies PTPRD as a candidate tumor suppressor gene in neuroblastoma. <i>Cancer Research</i> , <b>2006</b> , 66, 3673-80	10.1	112
54	Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 500-6	2.2	148
53	Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. <i>Cancer Research</i> , <b>2006</b> , 66, 6050-62	10.1	162



52	Pediatric horner syndrome: etiologies and roles of imaging and urine studies to detect neuroblastoma and other responsible mass lesions. <i>American Journal of Ophthalmology</i> , <b>2006</b> , 142, 651-9	4.9	112
51	Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma. <i>Pediatric Blood and Cancer</i> , <b>2006</b> , 47, 865-74	3	71
50	Chromosome 1p and 11q deletions and outcome in neuroblastoma. <i>New England Journal of Medicine</i> , <b>2005</b> , 353, 2243-53	59.2	415
49	Prospects for therapeutic inhibition of neuroblastoma angiogenesis. <i>Cancer Letters</i> , <b>2005</b> , 228, 171-9	9.9	34
48	Measurement and relevance of neuroblastoma DNA copy number changes in the post-genome era. <i>Cancer Letters</i> , <b>2005</b> , 228, 83-90	9.9	23
47	The biologic basis for neuroblastoma heterogeneity and risk stratification. <i>Current Opinion in Pediatrics</i> , <b>2005</b> , 17, 7-13	3.2	153
46	Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma. <i>Oncogene</i> , <b>2005</b> , 24, 2684-94	9.2	120
45	High-resolution detection and mapping of genomic DNA alterations in neuroblastoma. <i>Genes Chromosomes and Cancer</i> , <b>2005</b> , 43, 390-403	5	82
44	Tumor response and toxicity with multiple infusions of high dose 131I-MIBG for refractory neuroblastoma. <i>Pediatric Blood and Cancer</i> , <b>2005</b> , 44, 232-9	3	72
43	How does MYCN amplification make neuroblastomas behave aggressively? Still more questions than answers. <i>Pediatric Blood and Cancer</i> , <b>2005</b> , 45, 869-70	3	4
42	Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 6466-73	2.2	113
41	Desmoplastic small round cell tumor in the abdomen and pelvis: report of CT findings in 11 affected children and young adults. <i>American Journal of Roentgenology</i> , <b>2005</b> , 184, 1910-4	5.4	54
40	Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 6474-80	2.2	104
39	Proliferation of human neuroblastomas mediated by the epidermal growth factor receptor. <i>Cancer Research</i> , <b>2005</b> , 65, 9868-75	10.1	112
38	Region-specific detection of neuroblastoma loss of heterozygosity at multiple loci simultaneously using a SNP-based tag-array platform. <i>Genome Research</i> , <b>2005</b> , 15, 1168-76	9.7	17
37	Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. <i>Cancer Research</i> , <b>2004</b> , 64, 8816-20	10.1	404
36	Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 2452-60	2.2	92
35	Malignant pheochromocytoma: current status and initiatives for future progress. <i>Endocrine-Related Cancer</i> , <b>2004</b> , 11, 423-36	5.7	262

34	Germline PHOX2B mutation in hereditary neuroblastoma. <i>American Journal of Human Genetics</i> , <b>2004</b> , 75, 727-30	11	187
33	Targeted radiotherapy with submyeloablative doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma. <i>Journal of Pediatric Hematology/Oncology</i> , <b>2003</b> , 25, 769-73	1.2	46
32	Identification and high-resolution mapping of a constitutional 11q deletion in an infant with multifocal neuroblastoma. <i>Lancet Oncology</i> , <b>2003</b> , 4, 769-71	21.7	31
31	Drosophila Rheb GTPase is required for cell cycle progression and cell growth. <i>Journal of Cell Science</i> , <b>2003</b> , 116, 3601-10	5.3	131
30	Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features. <i>Clinical Cancer Research</i> , <b>2003</b> , 9, 3345-55	12.9	39
29	Tumor suppression by a rationally designed reversible inhibitor of methionine aminopeptidase-2. <i>Cancer Research</i> , <b>2003</b> , 63, 7861-9	10.1	41
28	Focus on embryonal malignancies. <i>Cancer Cell</i> , <b>2002</b> , 2, 447-50	24.3	58
27	Evidence for a hereditary neuroblastoma predisposition locus at chromosome 16p12-13. <i>Cancer Research</i> , <b>2002</b> , 62, 6651-8	10.1	49
26	Allelic deletion at chromosome bands 11q14-23 is common in neuroblastoma. <i>Medical and Pediatric Oncology</i> , <b>2001</b> , 36, 24-7		41
25	Comprehensive analysis of chromosome 1p deletions in neuroblastoma. <i>Medical and Pediatric Oncology</i> , <b>2001</b> , 36, 32-6		57
24	Analysis of genomic imprinting at 1p35-36 in neuroblastoma. <i>Medical and Pediatric Oncology</i> , <b>2001</b> , 36, 52-5		12
23	Identification of a 1-megabase consensus region of deletion at 1p36.3 in primary neuroblastomas. <i>Medical and Pediatric Oncology</i> , <b>2000</b> , 35, 512-5		21
22	Localization of a hereditary neuroblastoma predisposition gene to 16p12-p13. <i>Medical and Pediatric Oncology</i> , <b>2000</b> , 35, 526-30		23
21	Deletion of 11q23 is a frequent event in the evolution of MYCN single-copy high-risk neuroblastomas. <i>Medical and Pediatric Oncology</i> , <b>2000</b> , 35, 544-6		35
20	Inhibition of tumor growth in a human neuroblastoma xenograft model with TNP-470. <i>Medical and Pediatric Oncology</i> , <b>2000</b> , 35, 673-6		17
19	Familial dyserythropoietic anaemia and thrombocytopenia due to an inherited mutation in GATA1. <i>Nature Genetics</i> , <b>2000</b> , 24, 266-70	36.3	424
18	Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study. <i>Journal of Clinical Oncology</i> , <b>2000</b> , 18, 1888-99	2.2	124
17	A novel human processed gene, DAD-R, maps to 12p12 and is expressed in several organs. <i>FEBS Letters</i> , <b>2000</b> , 473, 233-6	3.8	1

16	Molecular biology of neuroblastoma. <i>Journal of Clinical Oncology</i> , <b>1999</b> , 17, 2264-79	2.2	492
15	Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. <i>Nature Genetics</i> , <b>1999</b> , 23, 166-75	36.3	897
14	Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. <i>Oncogene</i> , <b>1999</b> , 18, 4948-57	9.2	193
13	Familial neuroblastoma: a three-generation pedigree and a further association with Hirschsprung disease. <i>Medical and Pediatric Oncology</i> , <b>1997</b> , 28, 1-5		34
12	Novel regions of chromosomal loss in familial neuroblastoma by comparative genomic hybridization. <i>Genes Chromosomes and Cancer</i> , <b>1997</b> , 19, 176-84	5	43
11	Biology and genetics of human neuroblastomas. <i>The American Journal of Pediatric Hematology/oncology</i> , <b>1997</b> , 19, 93-101		180
10	Monosomy 7 myelodysplastic syndrome and other second malignant neoplasms in children with neurofibromatosis type 1 <b>1997</b> , 79, 1438		2
9	Physical mapping and genomic structure of the human TNFR2 gene. <i>Genomics</i> , <b>1996</b> , 35, 94-100	4.3	60
8	Cerebral metabolic effects of neonatal seizures measured with in vivo 31P NMR spectroscopy. <i>Annals of Neurology</i> , <b>1986</b> , 20, 513-9	9.4	99
7	31P nuclear magnetic resonance spectroscopy: noninvasive biochemical analysis of the ischemic extremity. <i>Journal of Vascular Surgery</i> , <b>1986</b> , 3, 411-20	3.5	79
6	31P nuclear magnetic resonance spectroscopic investigation of human neuroblastoma in situ. <i>New England Journal of Medicine</i> , <b>1985</b> , 312, 1500-5	59.2	153
5	Diagnosis and therapeutic evaluation of a pediatric case of cardiomyopathy using phosphorus-31 nuclear magnetic resonance spectroscopy. <i>Journal of the American College of Cardiology</i> , <b>1985</b> , 5, 745-9	15.1	69
4	Molecular oncology of neuroblastoma 669-678		
3	Somatic structural variation targets neurodevelopmental genes and identifies SHANK2 as a tumor suppressor in neuroblastoma		1
2	Epigenomic profiling of neuroblastoma cell lines		1
1	Epigenetic state determines inflammatory sensing in neuroblastoma		2